Although the combination of EGFR and MEK/ERK inhibitors has shown some clinical improvements in resistant EGFR-mutant NSCLC patients (Dagogo-Jack et al, 2019; Xie et al, 2021), the use of a tri-therapeutic osimertinib/trametinib/dabrafenib (BRAF inhibitor) treatment has recently demonstrated promising results in EGFR-mutant/BRAF V600E lung adenocarcinoma patients (Huang et al, 2019; Meng et al, 2020; Zhou et al, 2020; Ribeiro et al, 2021; Chimbangu et al, 2024). This evidence concerns the gene MAP2K7 and lung adenocarcinoma.